Business Description
Dianthus Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US2528281080
Description
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 758.62 | |||||
| Equity-to-Asset | 0.97 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 50.73 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 78.48 | |||||
| 9-Day RSI | 68.5 | |||||
| 14-Day RSI | 61.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 42.52 | |||||
| Quick Ratio | 42.52 | |||||
| Cash Ratio | 42.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -28.03 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -2064.7 | |||||
| Net Margin % | -1732.77 | |||||
| FCF Margin % | -1180.18 | |||||
| ROE % | -16.28 | |||||
| ROA % | -15.54 | |||||
| ROIC % | -809.16 | |||||
| ROC (Joel Greenblatt) % | -5776.55 | |||||
| ROCE % | -19.33 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 92.82 | |||||
| PB Ratio | 2.2 | |||||
| Price-to-Tangible-Book | 2.35 | |||||
| EV-to-EBIT | -9.35 | |||||
| EV-to-EBITDA | -9.39 | |||||
| EV-to-Revenue | 193.04 | |||||
| EV-to-FCF | -16.53 | |||||
| Price-to-Net-Current-Asset-Value | 2.36 | |||||
| Price-to-Net-Cash | 2.38 | |||||
| Earnings Yield (Greenblatt) % | -10.69 | |||||
| FCF Yield % | -3.31 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dianthus Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 2.089 | ||
| EPS (TTM) (€) | -4.693 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 61.97 | ||
| 14-Day ATR (€) | 0.932679 | ||
| 20-Day SMA (€) | 22.025 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 10.5 - 29.6 | ||
| Shares Outstanding (Mil) | 29.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dianthus Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dianthus Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Dianthus Therapeutics Inc Frequently Asked Questions
What is Dianthus Therapeutics Inc(FRA:87E)'s stock price today?
The current price of FRA:87E is €25.60. The 52 week high of FRA:87E is €29.60 and 52 week low is €10.50.
When is next earnings date of Dianthus Therapeutics Inc(FRA:87E)?
The next earnings date of Dianthus Therapeutics Inc(FRA:87E) is 2024-08-30 Est..
Does Dianthus Therapeutics Inc(FRA:87E) pay dividends? If so, how much?
Dianthus Therapeutics Inc(FRA:87E) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers